Single User License
INR 136740
Site License
INR 273480
Corporate User License
INR 410220

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Hepatitis C-Pipeline Review, H1 2015

Hepatitis C-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Hepatitis C-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Hepatitis C-Pipeline Review, H1 2015', provides an overview of the Hepatitis C's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hepatitis C, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatitis C and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Hepatitis C

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Hepatitis C and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Hepatitis C products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Hepatitis C pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Hepatitis C

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Hepatitis C pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 12

List of Figures 16

Introduction 17

Global Markets Direct Report Coverage 17

Hepatitis C Overview 18

Therapeutics Development 19

Pipeline Products for Hepatitis C-Overview 19

Pipeline Products for Hepatitis C-Comparative Analysis 20

Hepatitis C-Therapeutics under Development by Companies 21

Hepatitis C-Therapeutics under Investigation by Universities/Institutes 30

Hepatitis C-Pipeline Products Glance 33

Late Stage Products 33

Clinical Stage Products 34

Early Stage Products 35

Unknown Stage Products 36

Hepatitis C-Products under Development by Companies 37

Hepatitis C-Products under Investigation by Universities/Institutes 52

Hepatitis C-Companies Involved in Therapeutics Development 55

3-V Biosciences, Inc. 55

AbbVie Inc. 56

Achillion Pharmaceuticals, Inc. 57

Adaptimmune Limited 58

AiCuris GmbH & Co. KG 59

AIMM Therapeutics B.V. 60

Akshaya Bio Inc. 61

Alnylam Pharmaceuticals, Inc. 62

Altor BioScience Corporation 63

Amarna Therapeutics B.V. 64

American Gene Technologies International Inc. 65

Anacor Pharmaceuticals, Inc. 66

ARA Healthcare Pvt. Ltd. 67

Arrowhead Research Corporation 68

Ascendis Pharma A/S 69

Astex Pharmaceuticals, Inc. 70

Biogenomics Limited 71

BioLineRx, Ltd. 72

Bionor Pharma ASA 73

Biotest AG 74

Biotron Limited 75

Bolder Biotechnology, Inc. 76

Bristol-Myers Squibb Company 77

Celgene Corporation 78

Chiasma, Inc. 79

Chugai Pharmaceutical Co., Ltd. 80

Cocrystal Pharma, Inc. 81

Conatus Pharmaceuticals Inc. 82

Crucell N.V. 83

Debiopharm International S.A. 84

DEKK-TEC, Inc. 85

Delpor, Inc. 86

Digna Biotech, S.L. 87

DiscoveryBiomed, Inc. 88

Enanta Pharmaceuticals, Inc. 89

F. Hoffmann-La Roche Ltd. 90

Genecode AS 91

GeneCure LLC 92

Gilead Sciences, Inc. 93

GlaxoSmithKline plc 94

HanAll Biopharma Co., Ltd. 95

Hanmi Pharmaceuticals, Co. Ltd. 96

HEC Pharm Co., Ltd. 97

Hepacyl Therapeutics, SL 98

Hependo Sp. z o. o. (Ltd) 99

Hetero Drugs Limited 100

Humabs BioMed SA 101

ImmunoBiology Ltd. 102

Immunocore Limited 103

Immunomedics, Inc. 104

Immunotech Laboratories, Inc. 105

Inbiopro Solutions Pvt. Ltd. 106

Inovio Pharmaceuticals, Inc. 107

Integrated BioTherapeutics, Inc. 108

iTherX, Inc. 109

Johnson & Johnson 110

Kineta, Inc. 111

Koronis Pharma, Inc. 112

LG Life Sciences, Ltd. 113

Ligand Pharmaceuticals, Inc. 114

Meda AB 115

Medivir AB 116

Merck & Co., Inc. 117

Microbio Co., Ltd. 118

Microbiotix, Inc. 119

Myelo Therapeutics GmbH 120

Novartis AG 121

Oncolys BioPharma Inc. 122

Ono Pharmaceutical Co., Ltd. 123

Peregrine Pharmaceuticals, Inc. 124

Pfenex Inc. 125

Pfizer Inc. 126

PharmaEssentia Corporation 127

Polaris Pharmaceuticals, Inc. 128

Presidio Pharmaceuticals, Inc. 129

Profectus BioSciences, Inc. 130

Quintessence Biosciences, Inc. 131

Regulus Therapeutics Inc. 132

RFS Pharma, LLC 133

Rodos BioTarget GmbH 134

Romark Laboratories, L.C. 135

Seek 136

SelectX Pharmaceuticals, Inc. 137

SKAU Vaccines ApS 138

SomaGenics Inc. 139

Sorrento Therapeutics, Inc. 140

Spring Bank Pharmaceuticals, Inc. 141

StemCells, Inc. 142

Summit Corporation plc 143

Tacere Therapeutics, Inc. 144

TaiGen Biotechnology Co., Ltd. 145

Therapure Biopharma Inc. 146

Theravectys S.A. 147

Transgene SA 148

United Therapeutics Corporation 149

Vakzine Projekt Management GmbH 150

Vaxeal Holding SA 151

VBI Vaccines 152

Vertex Pharmaceuticals Incorporated 153

ViroLogik GmbH 154

WaterStone Pharmaceuticals, Inc. 155

WhanIn Pharmaceutical Co., Ltd. 156

Xenetic Biosciences plc 157

Hepatitis C-Therapeutics Assessment 158

Assessment by Monotherapy Products 158

Assessment by Combination Products 159

Assessment by Target 160

Assessment by Mechanism of Action 166

Assessment by Route of Administration 170

Assessment by Molecule Type 172

Drug Profiles 174

(asunaprevir + daclatasvir)-Drug Profile 174

(daclatasvir + asunaprevir + beclabuvir)-Drug Profile 176

(danoprevir + ritonavir)-Drug Profile 178

(grazoprevir + elbasvir)-Drug Profile 179

(ledipasvir + sofosbuvir)-Drug Profile 181

(ombitasvir + paritaprevir + ritonavir) + dasabuvir-Drug Profile 184

(paritaprevir + ritonavir + ombitasvir)-Drug Profile 187

(ribavirin + hydroxychloroquine)-Drug Profile 189

(sofosbuvir + GS-5816)-Drug Profile 190

ABT-493-Drug Profile 192

ABT-493 + ABT-530-Drug Profile 193

ABT-530-Drug Profile 195

ACH-3080-Drug Profile 196

ACH-3102-Drug Profile 197

ACH-3107-Drug Profile 198

ACH-3422-Drug Profile 199

ACP-007-Drug Profile 200

AG-1104-Drug Profile 201

AIC-649-Drug Profile 202

AL-335-Drug Profile 203

AL-516-Drug Profile 204

alisporivir-Drug Profile 205

Antiviral TCR-Ck-Drug Profile 207

Antiviral TCR-Ig-Drug Profile 208

ARABS-3-Drug Profile 209

ARABS-4-Drug Profile 210

ARABS-5-Drug Profile 211

asunaprevir-Drug Profile 212

AT-26893-Drug Profile 214

AV-4025-Drug Profile 215

AV-4203-Drug Profile 217

AVL-181-Drug Profile 218

AVL-192-Drug Profile 219

AVR-560-Drug Profile 220

bavituximab-Drug Profile 221

BBT-012-Drug Profile 226

beclabuvir-Drug Profile 227

BIT-225-Drug Profile 229

BIT-314-Drug Profile 231

BL-8030-Drug Profile 232

BZF-961-Drug Profile 233

CDI-244-Drug Profile 234

Cell Therapy for HCV/Diabetes-Drug Profile 235

CIGB-230-Drug Profile 236

CPI-43132-Drug Profile 238

Creaferon-Drug Profile 239

daclatasvir dihydrochloride-Drug Profile 240

DAG-181-Drug Profile 242

danoprevir-Drug Profile 243

dasabuvir-Drug Profile 245

DCBF-1-Drug Profile 247

deldeprevir-Drug Profile 248

Dendritic Cell Therapy for Hepatitis C-Drug Profile 249

Dimethylpyridine-Drug Profile 250

DL-2014-Drug Profile 251

DLP-201-Drug Profile 252

Drug for Hepatitis C Infections-Drug Profile 253

Drug for Infectious Diseases-Drug Profile 254

Drugs for HCV Infection-Drug Profile 255

Drugs to Antagonize Type I Interferon Receptor for Viral Infections-Drug Profile 256

Drugs to Inhibit NS5B for Hepatitis C-Drug Profile 257

E-2216-Drug Profile 258

EDP-239-Drug Profile 259

EDP-239 + alisporivir-Drug Profile 260

EDP-546-Drug Profile 261

elbasvir-Drug Profile 262

emricasan-Drug Profile 263

Fluoropyridone-19-Drug Profile 265

furaprevir-Drug Profile 266

Gene Therapy for Hepatitis B and Hepatitis C-Drug Profile 267

Gene Therapy for Hepatitis C-Drug Profile 268

grazoprevir-Drug Profile 269

GS-563253-Drug Profile 271

GS-5816-Drug Profile 272

GS-9256-Drug Profile 273

GS-9620-Drug Profile 274

GS-9669-Drug Profile 276

GS-9857-Drug Profile 277

GSK-2878175-Drug Profile 278

H-31356-Drug Profile 279

H-5C-Drug Profile 280

H-5CN-Drug Profile 282

Haprolid-Drug Profile 284

hepatitis C [Type 1, 6] vaccine-Drug Profile 285

hepatitis C immune globulin (human)-Drug Profile 286

hepatitis C vaccine-Drug Profile 288

hepatitis C vaccine-Drug Profile 289

hepatitis C vaccine-Drug Profile 290

hepatitis C vaccine-Drug Profile 291

hepatitis C vaccine-Drug Profile 292

hepatitis C vaccine-Drug Profile 293

hepatitis C vaccine-Drug Profile 294

hepatitis C vaccine-Drug Profile 295

hepatitis C vaccine-Drug Profile 296

hepatitis C Vaccine (H77)-Drug Profile 297

HepBioVax-Drug Profile 298

HL-143-Drug Profile 299

hLEC-Drug Profile 300

HM-10660A-Drug Profile 302

IBPB-006IA-Drug Profile 303

ID-12-Drug Profile 304

ID-4025-Drug Profile 305

IkT-064-Drug Profile 306

InferoXen-Drug Profile 307

Innate Immune Agonists-Drug Profile 308

INO-8000-Drug Profile 309

interferon alfa-2a (recombinant)-Drug Profile 310

interferon alfa-2a SR-Drug Profile 311

interferon alfa-2b-Drug Profile 312

interferon alfa-2b (recombinant)-Drug Profile 313

Interferon Alfa-5-Drug Profile 314

Interferon Lambda-1 Linked Fab Dimer-Drug Profile 315

ITV-1-Drug Profile 316

ITX-4520-Drug Profile 317

ITX-5061-Drug Profile 318

JNJ-42039556-Drug Profile 320

JNJ-47910382-Drug Profile 322

JNJ-56914845-Drug Profile 323

JT-16-Drug Profile 325

KW-2-Drug Profile 326

KW-5-Drug Profile 327

LCTA-949-Drug Profile 328

LG-7501-Drug Profile 329

MB-110-Drug Profile 330

MBL-HCV-1-Drug Profile 331

MBX-700-Drug Profile 332

MBX-701-Drug Profile 333

mericitabine-Drug Profile 334

miglustat-Drug Profile 336

miravirsen-Drug Profile 337

MIV-802-Drug Profile 339

MK-2248-Drug Profile 340

MK-2748-Drug Profile 341

MK-3682-Drug Profile 342

MK-7680-Drug Profile 343

MK-8408-Drug Profile 344

MK-8876-Drug Profile 345

Monoclonal Antibodies for Hepatitis C-Drug Profile 346

Monoclonal Antibodies for Hepatitis C-Drug Profile 347

Monoclonal Antibodies to Inhibit E2 Glycoprotein for HCV-Drug Profile 348

Monoclonal Antibodies to Inhibit Viral E1/E2 Proteins for Hepatitis C-Drug Profile 349

Monoclonal Antibody for Hepatitis C-Drug Profile 350

Monoclonal Antibody for Hepatitis C-Drug Profile 351

Monoclonal Antibody for Hepatitis C-Drug Profile 352

Monoclonal Antibody for Hepatitis C Infection-Drug Profile 353

Monoclonal Antibody to Inhibit CD3 for Autoimmune Disorders, CNS Disorders, Infectious Diseases, Liver Diseases, Metabolic Disorders and Cardiovascular Diseases-Drug Profile 354

Monoclonal Antibody to Inhibit HCV Envelope Protein E2 for Hepatitis C-Drug Profile 356

Myelo-001-Drug Profile 357

N-251-Drug Profile 358

N-89-Drug Profile 359

NA-255-Drug Profile 360

narlaprevir-Drug Profile 361

NICAM Program-Drug Profile 362

NICAM-44002-Drug Profile 364

nitazoxanide SR-Drug Profile 366

nivocasan-Drug Profile 368

nivolumab (recombinant)-Drug Profile 370

NVP-018-Drug Profile 375

OBPAI-001-Drug Profile 376

ombitasvir-Drug Profile 377

oncostatin M-Drug Profile 378

paritaprevir-Drug Profile 379

PEG-IFN-SA-Drug Profile 381

pegargiminase-Drug Profile 382

peginterferon alfa-2a-Drug Profile 386

peginterferon alfa-2a (recombinant)-Drug Profile 387

peginterferon alfa-2b-Drug Profile 388

peginterferon lambda-1a-Drug Profile 390

Peptide to Inhibit FOXP3 for Hepatitis and Oncology-Drug Profile 391

Peptides to Inhibit NS4B, 5A and 5B for Hepatitis C-Drug Profile 392

PPI-383-Drug Profile 393

PPI-668-Drug Profile 394

ProCvax-Drug Profile 396

Protein for Hepatitis C, Hepatitis B and Cancer-Drug Profile 397

Proteins to Inhibit NS3 Protease for Hepatitis C-Drug Profile 398

PTC-512-Drug Profile 399

PTC-725-Drug Profile 400

PTC-971-Drug Profile 401

RBT-05-Drug Profile 402

Recombinant Enzyme for Hepatitis C-Drug Profile 403

Recombinant Protein for HCV-Drug Profile 404

Recombinant Proteins for HCV infection-Drug Profile 405

RG-101-Drug Profile 406

RG-7109-Drug Profile 409

RNAi Oligonucleotide for Hepatitis C-Drug Profile 410

RNAi Oligonucleotide to Inhibit MicroRNA-122 for Hepatitis C-Drug Profile 411

RNAi Oligonucleotide to Target miR-122 for Hepatitis C-Drug Profile 413

RNAi Oligonucleotides for Hepatitis C-Drug Profile 414

rOAS-Drug Profile 415

RS-1137-Drug Profile 416

RS-1142-Drug Profile 417

RS-1145-Drug Profile 418

RS-930-Drug Profile 419

RS-961-Drug Profile 420

samatasvir-Drug Profile 421

SB-9200-Drug Profile 423

SCY-635-Drug Profile 425

setrobuvir-Drug Profile 427

silibinin-Drug Profile 429

SIRNA-034-Drug Profile 430

Small Molecule for Hepatitis C-Drug Profile 431

Small Molecule for Viral Diseases-Drug Profile 432

Small Molecule to Antagonize EGFR for Hepatitis C-Drug Profile 433

Small Molecule to Inhibit Cyclophilin for Hepatitis C-Drug Profile 434

Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections-Drug Profile 435

Small Molecule to Inhibit HCV Polymerase for Hepatitis C-Drug Profile 436

Small Molecule to Inhibit NS4B Protein for HCV-Drug Profile 437

Small Molecule to Inhibit NS5A for HCV-Drug Profile 438

Small Molecule to Inhibit NS5A for Hepatitis C-Drug Profile 439

Small Molecule to Inhibit NS5A for Hepatitis C Infections-Drug Profile 440

Small Molecule to Inhibit NS5B Polymerase for Hepatitis C-Drug Profile 441

Small Molecule to Inhibit RPS25 for Hepatitis C-Drug Profile 442

Small Molecule to Inhibit Viral RNA for Hepatitis C-Drug Profile 443

Small Molecules for Hepatitis C-Drug Profile 444

Small Molecules for Hepatitis C-Drug Profile 445

Small Molecules for Hepatitis C-Drug Profile 446

Small Molecules for Herpes Simplex and Hepatitis C Infections-Drug Profile 447

Small Molecules to Activate AMPK for Hepatitis C-Drug Profile 448

Small Molecules to Inhibit NS3 Helicase for Hepatitis C-Drug Profile 449

Small Molecules to Inhibit NS3 Protease and RNA Helicase for Hepatitis C-Drug Profile 450

Small Molecules to Inhibit NS3 Protease for Hepatitis C-Drug Profile 451

Small Molecules to Inhibit NS3 Protease for Hepatitis C-Drug Profile 452

Small Molecules to Inhibit NS3/4A Protease for Hepatitis C-Drug Profile 453

Small Molecules to Inhibit NS3/4A Serine Protease for Hepatitis C-Drug Profile 454

Small Molecules to inhibit NS5B Polymerase for HCV-Drug Profile 455

Small Molecules to Inhibit NS5B Polymerase for Hepatitis C-Drug Profile 456

Small Molecules to Inhibit NS5B Polymerase for Hepatitis C Virus Infection-Drug Profile 457

Small Molecules to Inhibit PI4KIIIbeta for HCV-Drug Profile 458

Small Molecules to Inhibit RNA Polymerase for Hepatitis C-Drug Profile 459

Small Molecules to Inhibit Viral Fusion for HIV, HCV and Influenza-Drug Profile 460

Small Molecules to Target Heparan Sulphate Proteoglycan for Bacterial and Viral Infections-Drug Profile 461

Small Molecules to Target IRES RNA for HCV Infection-Drug Profile 462

sofosbuvir-Drug Profile 463

sovaprevir-Drug Profile 466

Synthetic Peptide for Hepatitis C-Drug Profile 468

Synthetic Peptides to Inhibit E1 and E2 Glycoprotein for HCV-Drug Profile 469

Synthetic Peptides to Inhibit Hsp70 for Hepatitis C-Drug Profile 470

TBI-301-Drug Profile 471

TD-6450-Drug Profile 472

telaprevir-Drug Profile 473

TerCvax-Drug Profile 477

TG-4040-Drug Profile 479

thrombopoietin-Drug Profile 482

TT-033-Drug Profile 483

TT-034-Drug Profile 484

TVB-2640-Drug Profile 486

Vacc-HCV-Drug Profile 487

Vaccine to Target TLR2 for Infectious Disease-Drug Profile 488

vedroprevir-Drug Profile 489

VL-01-Drug Profile 490

VPM-5001-Drug Profile 491

Hepatitis C-Recent Pipeline Updates 492

Hepatitis C-Dormant Projects 585

Hepatitis C-Discontinued Products 604

Hepatitis C-Product Development Milestones 612

Featured News & Press Releases 612

Appendix 621

Methodology 621

Coverage 621

Secondary Research 621

Primary Research 621

Expert Panel Validation 621

Contact Us 622

Disclaimer 622

List of Tables

Number of Products under Development for Hepatitis C, H1 2015 36

Number of Products under Development for Hepatitis C-Comparative Analysis, H1 2015 37

Number of Products under Development by Companies, H1 2015 39

Number of Products under Development by Companies, H1 2015 (Contd..1) 40

Number of Products under Development by Companies, H1 2015 (Contd..2) 41

Number of Products under Development by Companies, H1 2015 (Contd..3) 42

Number of Products under Development by Companies, H1 2015 (Contd..4) 43

Number of Products under Development by Companies, H1 2015 (Contd..5) 44

Number of Products under Development by Companies, H1 2015 (Contd..6) 45

Number of Products under Development by Companies, H1 2015 (Contd..7) 46

Number of Products under Investigation by Universities/Institutes, H1 2015 48

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 49

Comparative Analysis by Late Stage Development, H1 2015 50

Comparative Analysis by Clinical Stage Development, H1 2015 51

Comparative Analysis by Early Stage Development, H1 2015 52

Comparative Analysis by Unknown Stage Development, H1 2015 53

Products under Development by Companies, H1 2015 54

Products under Development by Companies, H1 2015 (Contd..1) 55

Products under Development by Companies, H1 2015 (Contd..2) 56

Products under Development by Companies, H1 2015 (Contd..3) 57

Products under Development by Companies, H1 2015 (Contd..4) 58

Products under Development by Companies, H1 2015 (Contd..5) 59

Products under Development by Companies, H1 2015 (Contd..6) 60

Products under Development by Companies, H1 2015 (Contd..7) 61

Products under Development by Companies, H1 2015 (Contd..8) 62

Products under Development by Companies, H1 2015 (Contd..9) 63

Products under Development by Companies, H1 2015 (Contd..10) 64

Products under Development by Companies, H1 2015 (Contd..11) 65

Products under Development by Companies, H1 2015 (Contd..12) 66

Products under Development by Companies, H1 2015 (Contd..13) 67

Products under Development by Companies, H1 2015 (Contd..14) 68

Products under Investigation by Universities/Institutes, H1 2015 69

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 70

Products under Investigation by Universities/Institutes, H1 2015 (Contd..2) 71

Hepatitis C-Pipeline by 3-V Biosciences, Inc., H1 2015 72

Hepatitis C-Pipeline by AbbVie Inc., H1 2015 73

Hepatitis C-Pipeline by Achillion Pharmaceuticals, Inc., H1 2015 74

Hepatitis C-Pipeline by Adaptimmune Limited, H1 2015 75

Hepatitis C-Pipeline by AiCuris GmbH & Co. KG, H1 2015 76

Hepatitis C-Pipeline by AIMM Therapeutics B.V., H1 2015 77

Hepatitis C-Pipeline by Akshaya Bio Inc., H1 2015 78

Hepatitis C-Pipeline by Alnylam Pharmaceuticals, Inc., H1 2015 79

Hepatitis C-Pipeline by Altor BioScience Corporation, H1 2015 80

Hepatitis C-Pipeline by Amarna Therapeutics B.V., H1 2015 81

Hepatitis C-Pipeline by American Gene Technologies International Inc., H1 2015 82

Hepatitis C-Pipeline by Anacor Pharmaceuticals, Inc., H1 2015 83

Hepatitis C-Pipeline by ARA Healthcare Pvt. Ltd., H1 2015 84

Hepatitis C-Pipeline by Arrowhead Research Corporation, H1 2015 85

Hepatitis C-Pipeline by Ascendis Pharma A/S, H1 2015 86

Hepatitis C-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 87

Hepatitis C-Pipeline by Biogenomics Limited, H1 2015 88

Hepatitis C-Pipeline by BioLineRx, Ltd., H1 2015 89

Hepatitis C-Pipeline by Bionor Pharma ASA, H1 2015 90

Hepatitis C-Pipeline by Biotest AG, H1 2015 91

Hepatitis C-Pipeline by Biotron Limited, H1 2015 92

Hepatitis C-Pipeline by Bolder Biotechnology, Inc., H1 2015 93

Hepatitis C-Pipeline by Bristol-Myers Squibb Company, H1 2015 94

Hepatitis C-Pipeline by Celgene Corporation, H1 2015 95

Hepatitis C-Pipeline by Chiasma, Inc., H1 2015 96

Hepatitis C-Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 97

Hepatitis C-Pipeline by Cocrystal Pharma, Inc., H1 2015 98

Hepatitis C-Pipeline by Conatus Pharmaceuticals Inc., H1 2015 99

Hepatitis C-Pipeline by Crucell N.V., H1 2015 100

Hepatitis C-Pipeline by Debiopharm International S.A., H1 2015 101

Hepatitis C-Pipeline by DEKK-TEC, Inc., H1 2015 102

Hepatitis C-Pipeline by Delpor, Inc., H1 2015 103

Hepatitis C-Pipeline by Digna Biotech, S.L., H1 2015 104

Hepatitis C-Pipeline by DiscoveryBiomed, Inc., H1 2015 105

Hepatitis C-Pipeline by Enanta Pharmaceuticals, Inc., H1 2015 106

Hepatitis C-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 107

Hepatitis C-Pipeline by Genecode AS, H1 2015 108

Hepatitis C-Pipeline by GeneCure LLC, H1 2015 109

Hepatitis C-Pipeline by Gilead Sciences, Inc., H1 2015 110

Hepatitis C-Pipeline by GlaxoSmithKline plc, H1 2015 111

Hepatitis C-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 112

Hepatitis C-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 113

Hepatitis C-Pipeline by HEC Pharm Co., Ltd., H1 2015 114

Hepatitis C-Pipeline by Hepacyl Therapeutics, SL, H1 2015 115

Hepatitis C-Pipeline by Hependo Sp. z o. o. (Ltd), H1 2015 116

Hepatitis C-Pipeline by Hetero Drugs Limited, H1 2015 117

Hepatitis C-Pipeline by Humabs BioMed SA, H1 2015 118

Hepatitis C-Pipeline by ImmunoBiology Ltd., H1 2015 119

Hepatitis C-Pipeline by Immunocore Limited, H1 2015 120

Hepatitis C-Pipeline by Immunomedics, Inc., H1 2015 121

Hepatitis C-Pipeline by Immunotech Laboratories, Inc., H1 2015 122

Hepatitis C-Pipeline by Inbiopro Solutions Pvt. Ltd., H1 2015 123

Hepatitis C-Pipeline by Inovio Pharmaceuticals, Inc., H1 2015 124

Hepatitis C-Pipeline by Integrated BioTherapeutics, Inc., H1 2015 125

Hepatitis C-Pipeline by iTherX, Inc., H1 2015 126

Hepatitis C-Pipeline by Johnson & Johnson, H1 2015 127

Hepatitis C-Pipeline by Kineta, Inc., H1 2015 128

Hepatitis C-Pipeline by Koronis Pharma, Inc., H1 2015 129

Hepatitis C-Pipeline by LG Life Sciences, Ltd., H1 2015 130

Hepatitis C-Pipeline by Ligand Pharmaceuticals, Inc., H1 2015 131

Hepatitis C-Pipeline by Meda AB, H1 2015 132

Hepatitis C-Pipeline by Medivir AB, H1 2015 133

Hepatitis C-Pipeline by Merck & Co., Inc., H1 2015 134

Hepatitis C-Pipeline by Microbio Co., Ltd., H1 2015 135

Hepatitis C-Pipeline by Microbiotix, Inc., H1 2015 136

Hepatitis C-Pipeline by Myelo Therapeutics GmbH, H1 2015 137

Hepatitis C-Pipeline by Novartis AG, H1 2015 138

Hepatitis C-Pipeline by Oncolys BioPharma Inc., H1 2015 139

Hepatitis C-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 140

Hepatitis C-Pipeline by Peregrine Pharmaceuticals, Inc., H1 2015 141

Hepatitis C-Pipeline by Pfenex Inc., H1 2015 142

Hepatitis C-Pipeline by Pfizer Inc., H1 2015 143

Hepatitis C-Pipeline by PharmaEssentia Corporation, H1 2015 144

Hepatitis C-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 145

Hepatitis C-Pipeline by Presidio Pharmaceuticals, Inc., H1 2015 146

Hepatitis C-Pipeline by Profectus BioSciences, Inc., H1 2015 147

Hepatitis C-Pipeline by Quintessence Biosciences, Inc., H1 2015 148

Hepatitis C-Pipeline by Regulus Therapeutics Inc., H1 2015 149

Hepatitis C-Pipeline by RFS Pharma, LLC, H1 2015 150

Hepatitis C-Pipeline by Rodos BioTarget GmbH, H1 2015 151

Hepatitis C-Pipeline by Romark Laboratories, L.C., H1 2015 152

Hepatitis C-Pipeline by Seek, H1 2015 153

Hepatitis C-Pipeline by SelectX Pharmaceuticals, Inc., H1 2015 154

Hepatitis C-Pipeline by SKAU Vaccines ApS, H1 2015 155

Hepatitis C-Pipeline by SomaGenics Inc., H1 2015 156

Hepatitis C-Pipeline by Sorrento Therapeutics, Inc., H1 2015 157

Hepatitis C-Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2015 158

Hepatitis C-Pipeline by StemCells, Inc., H1 2015 159

Hepatitis C-Pipeline by Summit Corporation plc, H1 2015 160

Hepatitis C-Pipeline by Tacere Therapeutics, Inc., H1 2015 161

Hepatitis C-Pipeline by TaiGen Biotechnology Co., Ltd., H1 2015 162

Hepatitis C-Pipeline by Therapure Biopharma Inc., H1 2015 163

Hepatitis C-Pipeline by Theravectys S.A., H1 2015 164

Hepatitis C-Pipeline by Transgene SA, H1 2015 165

Hepatitis C-Pipeline by United Therapeutics Corporation, H1 2015 166

Hepatitis C-Pipeline by Vakzine Projekt Management GmbH, H1 2015 167

Hepatitis C-Pipeline by Vaxeal Holding SA, H1 2015 168

Hepatitis C-Pipeline by VBI Vaccines, H1 2015 169

Hepatitis C-Pipeline by Vertex Pharmaceuticals Incorporated, H1 2015 170

Hepatitis C-Pipeline by ViroLogik GmbH, H1 2015 171

Hepatitis C-Pipeline by WaterStone Pharmaceuticals, Inc., H1 2015 172

Hepatitis C-Pipeline by WhanIn Pharmaceutical Co., Ltd., H1 2015 173

Hepatitis C-Pipeline by Xenetic Biosciences plc, H1 2015 174

Assessment by Monotherapy Products, H1 2015 175

Assessment by Combination Products, H1 2015 176

Number of Products by Stage and Target, H1 2015 178

Number of Products by Stage and Mechanism of Action, H1 2015 184

Number of Products by Stage and Route of Administration, H1 2015 188

Number of Products by Stage and Molecule Type, H1 2015 190

Hepatitis C Therapeutics-Recent Pipeline Updates, H1 2015 509

Hepatitis C-Dormant Projects, H1 2015 602

Hepatitis C-Dormant Projects (Contd..1), H1 2015 603

Hepatitis C-Dormant Projects (Contd..2), H1 2015 604

Hepatitis C-Dormant Projects (Contd..3), H1 2015 605

Hepatitis C-Dormant Projects (Contd..4), H1 2015 606

Hepatitis C-Dormant Projects (Contd..5), H1 2015 607

Hepatitis C-Dormant Projects (Contd..6), H1 2015 608

Hepatitis C-Dormant Projects (Contd..7), H1 2015 609

Hepatitis C-Dormant Projects (Contd..8), H1 2015 610

Hepatitis C-Dormant Projects (Contd..9), H1 2015 611

Hepatitis C-Dormant Projects (Contd..10), H1 2015 612

Hepatitis C-Dormant Projects (Contd..11), H1 2015 613

Hepatitis C-Dormant Projects (Contd..12), H1 2015 614

Hepatitis C-Dormant Projects (Contd..13), H1 2015 615

Hepatitis C-Dormant Projects (Contd..14), H1 2015 616

Hepatitis C-Dormant Projects (Contd..15), H1 2015 617

Hepatitis C-Dormant Projects (Contd..16), H1 2015 618

Hepatitis C-Dormant Projects (Contd..17), H1 2015 619

Hepatitis C-Dormant Projects (Contd..18), H1 2015 620

Hepatitis C-Discontinued Products, H1 2015 621

Hepatitis C-Discontinued Products (Contd..1), H1 2015 622

Hepatitis C-Discontinued Products (Contd..2), H1 2015 623

Hepatitis C-Discontinued Products (Contd..3), H1 2015 624

Hepatitis C-Discontinued Products (Contd..4), H1 2015 625

Hepatitis C-Discontinued Products (Contd..5), H1 2015 626

Hepatitis C-Discontinued Products (Contd..6), H1 2015 627

Hepatitis C-Discontinued Products (Contd..7), H1 2015 628

List of Figures

Number of Products under Development for Hepatitis C, H1 2015 36

Number of Products under Development for Hepatitis C-Comparative Analysis, H1 2015 37

Number of Products under Development by Companies, H1 2015 38

Number of Products under Investigation by Universities/Institutes, H1 2015 47

Comparative Analysis by Late Stage Development, H1 2015 50

Comparative Analysis by Clinical Stage Development, H1 2015 51

Comparative Analysis by Early Stage Products, H1 2015 52

Assessment by Monotherapy Products, H1 2015 175

Assessment by Combination Products, H1 2015 176

Number of Products by Top 10 Targets, H1 2015 177

Number of Products by Stage and Top 10 Targets, H1 2015 177

Number of Products by Top 10 Mechanism of Actions, H1 2015 183

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 183

Number of Products by Top 10 Routes of Administration, H1 2015 187

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 187

Number of Products by Top 10 Molecule Types, H1 2015 189

Number of Products by Stage and Top 10 Molecule Types, H1 2015 189

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3-V Biosciences, Inc.

AbbVie Inc.

Achillion Pharmaceuticals, Inc.

Adaptimmune Limited

AiCuris GmbH & Co. KG

AIMM Therapeutics B.V.

Akshaya Bio Inc.

Alnylam Pharmaceuticals, Inc.

Altor BioScience Corporation

Amarna Therapeutics B.V.

American Gene Technologies International Inc.

Anacor Pharmaceuticals, Inc.

ARA Healthcare Pvt. Ltd.

Arrowhead Research Corporation

Ascendis Pharma A/S

Astex Pharmaceuticals, Inc.

Biogenomics Limited

BioLineRx, Ltd.

Bionor Pharma ASA

Biotest AG

Biotron Limited

Bolder Biotechnology, Inc.

Bristol-Myers Squibb Company

Celgene Corporation

Chiasma, Inc.

Chugai Pharmaceutical Co., Ltd.

Cocrystal Pharma, Inc.

Conatus Pharmaceuticals Inc.

Crucell N.V.

Debiopharm International S.A.

DEKK-TEC, Inc.

Delpor, Inc.

Digna Biotech, S.L.

DiscoveryBiomed, Inc.

Enanta Pharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

Genecode AS

GeneCure LLC

Gilead Sciences, Inc.

GlaxoSmithKline plc

HanAll Biopharma Co., Ltd.

Hanmi Pharmaceuticals, Co. Ltd.

HEC Pharm Co., Ltd.

Hepacyl Therapeutics, SL

Hependo Sp. z o. o. (Ltd)

Hetero Drugs Limited

Humabs BioMed SA

ImmunoBiology Ltd.

Immunocore Limited

Immunomedics, Inc.

Immunotech Laboratories, Inc.

Inbiopro Solutions Pvt. Ltd.

Inovio Pharmaceuticals, Inc.

Integrated BioTherapeutics, Inc.

iTherX, Inc.

Johnson & Johnson

Kineta, Inc.

Koronis Pharma, Inc.

LG Life Sciences, Ltd.

Ligand Pharmaceuticals, Inc.

Meda AB

Medivir AB

Merck & Co., Inc.

Microbio Co., Ltd.

Microbiotix, Inc.

Myelo Therapeutics GmbH

Novartis AG

Oncolys BioPharma Inc.

Ono Pharmaceutical Co., Ltd.

Peregrine Pharmaceuticals, Inc.

Pfenex Inc.

Pfizer Inc.

PharmaEssentia Corporation

Polaris Pharmaceuticals, Inc.

Presidio Pharmaceuticals, Inc.

Profectus BioSciences, Inc.

Quintessence Biosciences, Inc.

Regulus Therapeutics Inc.

RFS Pharma, LLC

Rodos BioTarget GmbH

Romark Laboratories, L.C.

Seek

SelectX Pharmaceuticals, Inc.

SKAU Vaccines ApS

SomaGenics Inc.

Sorrento Therapeutics, Inc.

Spring Bank Pharmaceuticals, Inc.

StemCells, Inc.

Summit Corporation plc

Tacere Therapeutics, Inc.

TaiGen Biotechnology Co., Ltd.

Therapure Biopharma Inc.

Theravectys S.A.

Transgene SA

United Therapeutics Corporation

Vakzine Projekt Management GmbH

Vaxeal Holding SA

VBI Vaccines

Vertex Pharmaceuticals Incorporated

ViroLogik GmbH

WaterStone Pharmaceuticals, Inc.

WhanIn Pharmaceutical Co., Ltd.

Xenetic Biosciences plc

Hepatitis C Therapeutic Products under Development, Key Players in Hepatitis C Therapeutics, Hepatitis C Pipeline Overview, Hepatitis C Pipeline, Hepatitis C Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com